Innovative Treatment Mainstay Medical offers ReActiv8, the first FDA-approved restorative neurostimulation device for chronic low back pain, positioning the company as a pioneer in neuromodulation solutions with significant potential for expansion in the pain management market.

Recent Funding Success The company secured a substantial $125 million in equity financing led by Gilde Healthcare, indicating strong investor confidence and providing resources for sales growth, clinical trials, and market penetration efforts.

Expanding Market Presence With subsidiaries across Ireland, the US, Australia, Germany, and the Netherlands, Mainstay Medical is strategically positioned to increase its geographical reach, offering opportunities to develop new markets and build sales channels internationally.

Clinical Validation Recent publication of a five-year follow-up study and the completion of the RESTORE clinical trial demonstrate clinical efficacy and safety, which can be leveraged to increase adoption among healthcare providers and secure partnerships with hospitals.

Market Growth Opportunities Given the rising prevalence of chronic low back pain and the growing acceptance of neuromodulation therapies, Mainstay Medical is well-placed to capitalize on industry trends and expand sales through targeted outreach to pain clinics, neurologists, and orthopedic specialists.